ClinicalTrials.gg
CompletedNCT01986101Updated Apr 12, 2022Results posted

A Phase III Study of SM-13496 in Patients With Bipolar I Depression.

A Phase 3 interventional study of Placebo and SM-13496 in Bipolar Depression, sponsored by Sumitomo Pharma Co., Ltd.. Completed at 8 sites in 8 countries. Open to participants aged 18 Years to 74 Years. Per ClinicalTrials.gov, last updated 2022-04-12.

Sponsored by Sumitomo Pharma Co., Ltd. · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
525
Allocation
Randomized
Ages
18 Years to 74 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 17 studies testing lurasidone in Bipolar Disorder — 2 open to participants now, 2 under way, none of them phase 3. lurasidone · Bipolar Disorder.

Enrollment
4th of 17
525 · median 348
Started
2014
with 2 others
Phase 3
11 of 17
none open now
Registered
10th of 17
by date
Lead sponsor
1 of 17
Sumitomo Pharma Co., Ltd.

Among the 17 studies testing lurasidone in Bipolar Disorder, this one is the 4th largest by enrollment, is one of 3 that started in 2014, is one of 11 in phase 3, and was the 10th registered.

Bipolar Disorder

1,685 studies on the registry are indexed under Bipolar Disorder; 268 are open to participants now.

Browse Bipolar Disorder studies →

Open to participants now

2 of the 17 studies testing lurasidone in Bipolar Disorder are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About lurasidone

lurasidone: first FDA approval 2010 (LATUDA), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 208 Bipolar Disorder studies recruiting now, 59 (28%) set no upper age limit and 136 (65%) stop at 75 or younger; 38 take children under 18; 51 take healthy volunteers.

This study: 18 Years to 74 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 17 studies testing lurasidone in Bipolar Disorder, or all of them as a file.
02

Study summary

The study evaluates the efficacy and safety of SM-13496 compared with placebo in patients with Bipolar I Depression.

Read the detailed description

The primary objective is to compare the efficacy of SM-13496 (20-60 or 80-120 mg/day) monotherapy with that of placebo in patients with depressive symptoms associated with bipolar I disorder by assessing the change from baseline in the MADRS total score at Week 6.

03

Conditions studied

  • Bipolar Depression

Browse trials for

04

Who can participate

Ages eligible
18 Years to 74 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients who were fully informed of and understand the objectives, procedures, and possible benefits and risks of the study and who provided written voluntary consent to participate in the study.
  • Outpatients aged 18 through 74 years at the time of consent
  • Patients meets criteria for bipolar I disorder, most recent episode depressed (≥ 4 weeks and less than 12 months) without psychotic features.

Exclusion criteria

Exclusion Criteria:

  • Patients with imminent risk of suicide or injury to self, others, or property.
  • Patients who had been hospitalized because of a manic or mixed episode within 60 days prior to screening.
  • Patients who are otherwise considered ineligible for the study by the investigator.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
525 participants (actual)

Study arms

  • Placebo comparator
    Placebo

    once daily orally

    Drug: Placebo

  • Experimental
    SM-13496 20 - 60 mg/day

    once daily orally

    Drug: SM-13496

  • Experimental
    SM-13496 80 - 120 mg/day

    once daily orally

    Drug: SM-13496

Interventions

  • DrugPlacebo

    Placebo comparator

  • SM-13496 20mg for Days 1-7 and beginning Day 8 flexibly dosed 20-60 mg/day for Weeks 2-6

    Also known as: Lurasidone HCl

  • SM-13496 20 mg/day for Days 1-2, 40 mg/day for Days 3-4, 60 mg/day for Days 5-6, 80 mg/day on Day 7 and beginning Day 8 flexibly dosed 80-120 mg/day for Weeks 2-6

    Also known as: Lurasidone HCl

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score at Week 6

    Montgomery-Asberg Depression Rating Scale (MADRS)is a clinician-rated assessment of a subject's level of depression. The MADRS total score ranges from a minimum of 0 to a maximum of 60. For the MADRS total score, low scores indicate a better outcome and high scores indicate a worse outcome. When change from baseline is considered, a negative (decrease in score) value is considered a better outcome, and a positive (increase in score) value is considered a worse outcome. The MADRS contains ten (10) items. The total score is computed as the sum of the scores for the 10 items.

    Time frame: Baseline to 6 weeks

Secondary outcomes

  1. Change From Baseline in the CGI-BP-S (Depression) Score at Week 6

    Clinical Global Impression Bipolar Version, Severity of Illness (CGI-BP-S) score (depression) is a clinician-rated assessment of a subject's level of depression. The CGI depression score ranges from a minimum of 1 to a maximum of 7. For the CGI depression score, low scores indicate a better outcome and high scores indicate a worse outcome. When change from baseline is considered, a negative (decrease in score) value is considered a better outcome, and a positive (increase in score) value is considered a worse outcome.

    Time frame: Baseline to 6 weeks

  2. Change From Baseline in the SDS Total Score at Week 6 (LOCF)

    Sheehan Disability Scale (SDS) total score is a subject-rated assessment of a subject's level of functional impairment in work/school, social life and family life/home responsibilities. The SDS total score ranges from a minimum of 0 to a maximum of 30. For the SDS total score, low scores indicate a better outcome and high scores indicate a worse outcome. When change from baseline is considered, a negative (decrease in score) value is considered a better outcome, and a positive (increase in score) value is considered a worse outcome. The SDS contains three (3) items. The total score is computed as the sum of the scores for the 3 items.

    Time frame: Baseline to 6 weeks

  3. Change From Baseline in the YMRS Total Score at Week 6

    YMRS (Young Mania Rating Scale) is a clinician-rated assessment of the severity of mania in subjects with a diagnosis of bipolar disorder. The YMRS total score ranges from a minimum of 0 to a maximum of 60. For the YMRS total score, low scores indicate a better outcome and high scores indicate a worse outcome. When change from baseline is considered, a negative (decrease in score) value is considered a better outcome, and a positive (increase in score) value is considered a worse outcome. The YMRS contains eleven (11) items. The total score is computed as the sum of the scores for the 11 items.

    Time frame: Baseline to 6 weeks

  4. Change From Baseline in the HAM-A Total Score at Week 6 (LOCF)

    The Hamilton Rating Scale for Anxiety (HAM-A) scale is a rating scale developed to quantify the severity of anxiety symptomatology. The HAM-A total score ranges from a minimum of 0 to a maximum of 56. For the HAM-A total score, low scores indicate a better outcome and high scores indicate a worse outcome. When change from baseline is considered, a negative (decrease in score) value is considered a better outcome, and a positive (increase in score) value is considered a worse outcome. The HAM-A contains fourteen (14) items. The total score is computed as the sum of the scores for the 14 items.

    Time frame: Baseline to 6 weeks

07

Results

Posted Jul 25, 2019

Participant flow

Participant flow — Overall Study
MilestonePlaceboSM-13496 20 - 60 mg/DaySM-13496 80 - 120 mg/Day
Started172184169
Intent-to-treat population171182169
Safety population172184169
Completed139157137
Not completed332732

Outcome measures

PrimaryChange From Baseline in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score at Week 6

Montgomery-Asberg Depression Rating Scale (MADRS)is a clinician-rated assessment of a subject's level of depression. The MADRS total score ranges from a minimum of 0 to a maximum of 60. For the MADRS total score, low scores indicate a better outcome and high scores indicate a worse outcome. When change from baseline is considered, a negative (decrease in score) value is considered a better outcome, and a positive (increase in score) value is considered a worse outcome. The MADRS contains ten (10) items. The total score is computed as the sum of the scores for the 10 items.

Time frame:
Baseline to 6 weeks
Reported as:
Least squares mean · units on a scale
Change From Baseline in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score at Week 6
units on a scalePlaceboSM-13496 20 - 60 mg/DaySM-13496 80 - 120 mg/Day
Change From Baseline in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score at Week 6-10.6 ± 0.72-13.6 ± 0.69-12.6 ± 0.73
Statistical analysis
  • Placebo vs SM-13496 20 - 60 mg/Day · Mixed Models Analysis · p = 0.007 (Hochberg-adjusted) · Mean difference (final values): -2.9 · 95% CI -4.9 to -1.0A negative difference in least square mean change from baseline between SM-13496 group and placebo indicates a greater improvement in the SM-13496 group over the placebo group.
  • Placebo vs SM-13496 80 - 120 mg/Day · Mixed Models Analysis · p = 0.057 (Hochberg-adjusted.) · Mean difference (final values): -2.0 · 95% CI -4.0 to 0.1A negative difference in least square mean change from baseline between SM-13496 group and placebo indicates a greater improvement in the SM-13496 group over the placebo group.
SecondaryChange From Baseline in the CGI-BP-S (Depression) Score at Week 6

Clinical Global Impression Bipolar Version, Severity of Illness (CGI-BP-S) score (depression) is a clinician-rated assessment of a subject's level of depression. The CGI depression score ranges from a minimum of 1 to a maximum of 7. For the CGI depression score, low scores indicate a better outcome and high scores indicate a worse outcome. When change from baseline is considered, a negative (decrease in score) value is considered a better outcome, and a positive (increase in score) value is considered a worse outcome.

Time frame:
Baseline to 6 weeks
Reported as:
Least squares mean · units on a scale
Change From Baseline in the CGI-BP-S (Depression) Score at Week 6
units on a scalePlaceboSM-13496 20 - 60 mg/DaySM-13496 80 - 120 mg/Day
Change From Baseline in the CGI-BP-S (Depression) Score at Week 6-1.11 ± 0.092-1.51 ± 0.088-1.41 ± 0.093
Statistical analysis
  • Placebo vs SM-13496 20 - 60 mg/Day · Mixed Models Analysis · p = 0.002 · Mean difference (final values): -0.40 · 95% CI -0.65 to -0.15A negative difference in least square mean change from baseline between SM-13496 group and placebo indicates a greater improvement in the SM-13496 group over the placebo group.
  • Placebo vs SM-13496 80 - 120 mg/Day · Mixed Models Analysis · p = 0.019 · Mean difference (final values): -0.31 · 95% CI -0.56 to -0.05A negative difference in least square mean change from baseline between SM-13496 group and placebo indicates a greater improvement in SM-13496 group over the placebo group.
SecondaryChange From Baseline in the SDS Total Score at Week 6 (LOCF)

Sheehan Disability Scale (SDS) total score is a subject-rated assessment of a subject's level of functional impairment in work/school, social life and family life/home responsibilities. The SDS total score ranges from a minimum of 0 to a maximum of 30. For the SDS total score, low scores indicate a better outcome and high scores indicate a worse outcome. When change from baseline is considered, a negative (decrease in score) value is considered a better outcome, and a positive (increase in score) value is considered a worse outcome. The SDS contains three (3) items. The total score is computed as the sum of the scores for the 3 items.

Time frame:
Baseline to 6 weeks
Reported as:
Least squares mean · units on a scale
Change From Baseline in the SDS Total Score at Week 6 (LOCF)
units on a scalePlaceboSM-13496 20 - 60 mg/DaySM-13496 80 - 120 mg/Day
Change From Baseline in the SDS Total Score at Week 6 (LOCF)-5.7 ± 0.66-7.6 ± 0.62-6.8 ± 0.67
Statistical analysis
  • Placebo vs SM-13496 20 - 60 mg/Day · ANCOVA · p = 0.037 · Mean difference (final values): -1.8 · 95% CI -3.6 to -0.1A negative difference in least square mean change from baseline between SM-13496 group and placebo indicates a greater improvement in the SM-13496 group over the placebo group.
  • Placebo vs SM-13496 80 - 120 mg/Day · ANCOVA · p = 0.223 · Mean difference (final values): -1.1 · 95% CI -2.9 to 0.7A negative difference in least square mean change from baseline between SM-13496 group and placebo indicates a greater improvement in the SM-13496 group over the placebo group.
SecondaryChange From Baseline in the YMRS Total Score at Week 6

YMRS (Young Mania Rating Scale) is a clinician-rated assessment of the severity of mania in subjects with a diagnosis of bipolar disorder. The YMRS total score ranges from a minimum of 0 to a maximum of 60. For the YMRS total score, low scores indicate a better outcome and high scores indicate a worse outcome. When change from baseline is considered, a negative (decrease in score) value is considered a better outcome, and a positive (increase in score) value is considered a worse outcome. The YMRS contains eleven (11) items. The total score is computed as the sum of the scores for the 11 items.

Time frame:
Baseline to 6 weeks
Reported as:
Least squares mean · units on a scale
Change From Baseline in the YMRS Total Score at Week 6
units on a scalePlaceboSM-13496 20 - 60 mg/DaySM-13496 80 - 120 mg/Day
Change From Baseline in the YMRS Total Score at Week 6-0.51 ± 0.190-0.98 ± 0.180-0.99 ± 0.191
Statistical analysis
  • Placebo vs SM-13496 20 - 60 mg/Day · Mixed Models Analysis · p = 0.076 · Mean difference (final values): -0.47 · 95% CI -0.98 to 0.05A negative difference in least square mean change from baseline between SM-13496 group and placebo indicates a greater improvement in the SM-13496 group over the placebo group.
  • Placebo vs SM-13496 80 - 120 mg/Day · Mixed Models Analysis · p = 0.075 · Mean difference (final values): -0.48 · 95% CI -1.01 to 0.05A negative difference in least square mean change from baseline between SM-13496 group and placebo indicates a greater improvement in the SM-13496 group over the placebo group.
SecondaryChange From Baseline in the HAM-A Total Score at Week 6 (LOCF)

The Hamilton Rating Scale for Anxiety (HAM-A) scale is a rating scale developed to quantify the severity of anxiety symptomatology. The HAM-A total score ranges from a minimum of 0 to a maximum of 56. For the HAM-A total score, low scores indicate a better outcome and high scores indicate a worse outcome. When change from baseline is considered, a negative (decrease in score) value is considered a better outcome, and a positive (increase in score) value is considered a worse outcome. The HAM-A contains fourteen (14) items. The total score is computed as the sum of the scores for the 14 items.

Time frame:
Baseline to 6 weeks
Reported as:
Least squares mean · units on a scale
Change From Baseline in the HAM-A Total Score at Week 6 (LOCF)
units on a scalePlaceboSM-13496 20 - 60 mg/DaySM-13496 80 - 120 mg/Day
Change From Baseline in the HAM-A Total Score at Week 6 (LOCF)-5.7 ± 0.51-7.4 ± 0.49-6.4 ± 0.50
Statistical analysis
  • Placebo vs SM-13496 20 - 60 mg/Day · ANCOVA · p = 0.016 · Mean difference (final values): -1.7 · 95% CI -3.1 to -0.3A negative difference in least square mean change from baseline between SM-13496 group and placebo indicates a greater improvement in the SM-13496 group over the placebo group.
  • Placebo vs SM-13496 80 - 120 mg/Day · ANCOVA · p = 0.294 · Mean difference (final values): -0.7 · 95% CI -2.1 to 0.7A negative difference in least square mean change from baseline between SM-13496 group and placebo indicates a greater improvement in the SM-13496 group over the placebo group.

Adverse events

Collected over 6 weeks. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo0/172 (0%)5/172 (2.9%)44/172 (25.6%)
SM-13496 20 - 60 mg/Day0/184 (0%)2/184 (1.1%)49/184 (26.6%)
SM-13496 80 - 120 mg/Day0/169 (0%)4/169 (2.4%)75/169 (44.4%)
Most frequent serious events
Most frequent serious events
EventPlaceboSM-13496 20 - 60 mg/DaySM-13496 80 - 120 mg/Day
Disease progressionGeneral disorders1/1720/1841/169
Tendon ruptureInjury, poisoning and procedural complications0/1720/1841/169
Panic attackPsychiatric disorders0/1720/1841/169
Suicide attemptPsychiatric disorders0/1720/1841/169
Acute myocardial infarctionCardiac disorders1/1720/1840/169
Abdominal painGastrointestinal disorders1/1720/1840/169
Bipolar I disorderPsychiatric disorders1/1720/1840/169
ManiaPsychiatric disorders1/1721/1840/169
Suicidal ideationPsychiatric disorders0/1721/1840/169
Most frequent other events
Most frequent other events
EventPlaceboSM-13496 20 - 60 mg/DaySM-13496 80 - 120 mg/Day
AkathisiaNervous system disorders11/17224/18440/169
NauseaGastrointestinal disorders10/17212/18420/169
HeadacheNervous system disorders15/1725/1849/169
SomnolenceNervous system disorders7/1727/18411/169
ParkinsonismNervous system disorders4/1724/18410/169
NasopharyngitisInfections and infestations8/17210/1846/169

Baseline characteristics

Intention-to-treat population is analyzed.

Age, Continuous
Age, Continuous(years)PlaceboSM-13496 20 - 60 mg/DaySM-13496 80 - 120 mg/DayTotal
Mean41.3 ± 12.6442.6 ± 12.8643.2 ± 12.7842.4 ± 12.77
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboSM-13496 20 - 60 mg/DaySM-13496 80 - 120 mg/DayTotal
Female949588277
Male778781245
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)PlaceboSM-13496 20 - 60 mg/DaySM-13496 80 - 120 mg/DayTotal
White94105103302
Asian777766220
Region of Enrollment
Region of Enrollment(Participants)PlaceboSM-13496 20 - 60 mg/DaySM-13496 80 - 120 mg/DayTotal
Japan606553178
Philippines53311
Taiwan53412
Ukraine434345131
Malaysia76619
Slovakia57416
Lithuania24410
Russia445150145
Montgomery-Åsberg Depression Rating Scale (MADRS) Total Score
Montgomery-Åsberg Depression Rating Scale (MADRS) Total Score(units on a scale)PlaceboSM-13496 20 - 60 mg/DaySM-13496 80 - 120 mg/DayTotal
Mean30.9 ± 5.3930.6 ± 5.5730.8 ± 5.0930.8 ± 5.35
Clinical Global Impression Bipolar Version, Severity of Illness (CGI-BP-S) Score (Depression)
Clinical Global Impression Bipolar Version, Severity of Illness (CGI-BP-S) Score (Depression)(units on a scale)PlaceboSM-13496 20 - 60 mg/DaySM-13496 80 - 120 mg/DayTotal
Mean4.60 ± 0.6904.57 ± 0.7004.58 ± 0.6034.58 ± 0.666
Sheehan Disability Scale (SDS) total score
Sheehan Disability Scale (SDS) total score(units on a scale)PlaceboSM-13496 20 - 60 mg/DaySM-13496 80 - 120 mg/DayTotal
Mean19.9 ± 5.2219.4 ± 5.2919.8 ± 5.5819.7 ± 5.35
08

Study locations

8 sites
  • Japan 76 sites
    Tokyo, Japan
  • Lithuania 3 sites
    Kaunas, Lithuania
  • Malaysia 5 sites
    Kuala Lumpur, Malaysia
  • Philippines 4 sites
    Manila, Philippines
  • Russia 19 sites
    Moscow, Russian Federation
  • Slovakia 5 sites
    Zilina, Slovakia
  • Taiwan 7 sites
    Taipei, Taiwan
  • Ukraine 9 sites
    Kiev, Ukraine
09

References and documents

Publications

  • Kato T, Ishigooka J, Miyajima M, Watabe K, Fujimori T, Masuda T, Higuchi T, Vieta E. Double-blind, placebo-controlled study of lurasidone monotherapy for the treatment of bipolar I depression. Psychiatry Clin Neurosci. 2020 Dec;74(12):635-644. doi: 10.1111/pcn.13137. Epub 2020 Sep 24. PubMed 32827348 ↗
  • Kishi T, Yoshimura R, Sakuma K, Okuya M, Iwata N. Lurasidone, olanzapine, and quetiapine extended-release for bipolar depression: A systematic review and network meta-analysis of phase 3 trials in Japan. Neuropsychopharmacol Rep. 2020 Dec;40(4):417-422. doi: 10.1002/npr2.12137. Epub 2020 Sep 9. PubMed 32902200 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Undecided

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2014 to primary completion in Feb 2017, 35 months.

Results were first posted in Jul 2019, 2 years 5 months after primary completion.

Of 29 industry-sponsored phase 3 interventional studies under Bipolar Disorder, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 49. This study's 35 months is close to that.

Counting every sponsor, half of 43 studies reached it within 37 months; a quarter within 21 and three quarters within 60.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 4, 2013
First posted
Nov 18, 2013
StartActual
Feb 19, 2014
Primary completionActual
Feb 1, 2017
CompletionActual
Feb 16, 2017
Results first posted
Jul 25, 2019
Last update
Apr 12, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 12, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01986101
Responsible party
Sponsor
First posted
Nov 18, 2013
Start date
Feb 19, 2014
Primary completion
Feb 1, 2017
Completion
Feb 16, 2017
Results posted
Jul 25, 2019
Last update
Apr 12, 2022

Study contacts

Director, Drug Development Division
study director · Sumitomo Pharma Co., Ltd.

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Lurasidone

Start the discussion